COSCIENS BIOPHARMA

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders bit.ly/4jnlwdH $CSCI

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders bit.ly/45qgZnm $CSCI

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update bit.ly/44yekI5 $CSCI #Therapeutics

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer bit.ly/3G89sPL $CSCI #therapeutics

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update bit.ly/3YpZnDP $CSCI #Therapeutics

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product bit.ly/41L14g4 $CSCI #CoSciencs

Advancing a Priority Pipeline Beyond Successful Base-Business $CSCI #CoSciencs

Transforming Health Through Natural Based Products​ $CSCI #CoSciencs

Wishing you a #HappyNewYear filled with joy, new beginnings, and endless opportunities. Here’s to making 2025 your best year yet!

Stay in the loop with Cosciencs! Sign up for alerts and be the first to know about our latest updates. bit.ly/3AvH2vY #CoSciencs $CSCI

We are focused on leveraging our research and clinical development expertise to advance medicines that improve the quality of life of patients with significant unmet medical needs across a range of therapeutic areas. $CSCI #CoSciencs

Establishing #COSCIENS as a global leader in the development and commercialization of therapeutic assets that have the potential to enhance the lives of patients in need. bit.ly/408fOVJ $CSCI

Wishing you a peaceful and joyful holiday season. #HappyHolidays

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization bit.ly/4fCRwbL $CSCI #Therapeutics

We are a specialty biopharmaceutical company dedicated to advancing health and wellness through our innovative portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. bit.ly/408fOVJ

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs bit.ly/3AGJIrd $CSCI #Diagnostics #Therapeutics

COSCIENS Biopharma Announces Change to Board of Directors bit.ly/4eUMFCO $CSCI #Diagnostics #Therapeutics

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director bit.ly/3ZInjnB $CSCI #Diagnostics #Therapeutics

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs bit.ly/3MU1sSj $CSCI #Diagnostics #Therapeutics

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency bit.ly/4dCNBLT $CSCI #Therapeutics